Ibuprofeno B. Braun (Ibuprofen)

The ibuprofen in Ibuprofeno B. Braun reversibly blocks COX‑1 and COX‑2 enzymes, which reduces the synthesis of prostaglandins. Lower prostaglandin levels diminish peripheral nociceptor sensitisation, lower the hypothalamic temperature set‑point, and limit inflammatory mediators, producing pain relief, fever reduction, and decreased swelling.

The specific dose and infusion rate of Ibuprofeno B. Braun are determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and response to therapy. Healthcare professionals should follow institutional protocols and the product’s prescribing information when selecting the appropriate regimen.

Ibuprofeno B. Braun is classified as pregnancy category D, indicating potential risk to the fetus, especially after the first trimester. Use is reserved for situations where the therapeutic benefit justifies the risk. Limited data are available for breastfeeding; clinicians should weigh potential infant exposure against maternal benefit.

To request Ibuprofeno B. Braun, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Compared with oral NSAIDs, the intravenous route of Ibuprofeno B. Braun offers rapid onset of action and predictable plasma concentrations, which can be advantageous in acute pain or when oral administration is not feasible. Its safety profile is similar to other ibuprofen products, but the IV formulation avoids gastrointestinal irritation associated with oral dosing.

Ibuprofeno B. Braun should be stored at ambient temperature, protected from light and moisture, and kept in its original packaging until use. Do not freeze the solution. Inspect the vial for particulate matter or discoloration before administration, and discard any product that appears compromised.

The product is supplied as a sterile injectable solution for intravenous infusion. It is administered by a healthcare professional using aseptic technique, typically diluted in compatible IV fluids and infused over a period dictated by the prescribed dose and patient tolerance. Monitoring during infusion is recommended.

Serious adverse events include gastrointestinal bleeding or ulceration, acute renal failure, severe hypersensitivity reactions such as anaphylaxis, and rare hematologic or hepatic complications. Patients with a history of ulcer disease, renal impairment, or bleeding disorders should be closely monitored, and therapy should be discontinued if serious reactions occur.

Ibuprofeno B. Braun is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, active gastrointestinal bleeding or ulceration, severe uncontrolled heart failure, and in the third trimester of pregnancy. Caution is also advised for individuals with significant renal, hepatic or cardiovascular disease.